Durability of Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Booster Vaccine Protection Against Omicron Among Healthcare Workers With a Vaccine Mandate
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Background: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant has spread rapidly throughout the world since being identified in South Africa in November 2021. Few studies have assessed primary series and booster vaccine effectiveness against Omicron among US healthcare workers Methods: We conducted a test-negative case-control design to estimate BNT162b2 and mRNA1273 primary vaccination and booster effectiveness against SARS-CoV-2 infection and symptomatic coronavirus disease 2019 during an Omicron surge among employees of the University of Pennsylvania Health System. The study period was between 1 July 2021 and 5 April 2022. We defined the Delta period as 1 July to 12 December 2021 and the Omicron period as beginning 12 December 21. Results: Our sample included 14 520 tests (2776 [19%] positive)—7422 (506 [7%] positive) during Delta and 7098 (2270 [32%] positive) during Omicron. Benchmarked against Delta, the vaccine effectiveness of 2 vaccine doses was lower during Omicron, with no significant protection against infection. Booster doses added significant protection, although they also showed reduced effectiveness during Omicron. Compared with findings in employees who had received 2 vaccine doses, 3 doses of BNT162b2 had a relative effectiveness of 50% (95% confidence interval, 42%–56%) during Omicron, relative to 78% (63%–87%) during Delta; 3 doses of mRNA1273 had a relative effectiveness of 56% (45%–65%) during Omicron, relative to 96% (82%–99%) during Delta. Restricting the sample to symptomatic tests yielded similar results to our primary analysis. After initial waning in BNT162b2 booster protection against infection, it remained largely stable for ≥16 weeks after vaccination. Conclusions: Our findings provide a strong rationale for boosters among healthcare workers in the Omicron era.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Detection of a SARS-CoV-2 variant of concern in South Africa
Tegally, H., Wilkinson, E., Giovanetti, M., Iranzadeh, A., Fonseca, V., Giandhari, J., Doolabh, D., Pillay, S., San, E. J., Msomi, N., et al. (2021) · Nature · doi:10.1038/s41586-021-03402-9 · Cited by 2,510 · cited 1×
“The SARS-CoV-2 Omicron variant has spread rapidly throughout the world since being identified in South Africa inNovember 2021 [1], and it includes common sublineages BA.”
BackgroundEffectiveness of COVID-19 vaccines against the Omicron (B.1.1.529) variant of concern
Andrews, N., Stowe, J., Kirsebom, F., Toffa, S., Rickeard, T., Gallagher, E., Gower, C., Kall, M., Groves, N., O’Connell, A.-M., et al. (2021) · doi:10.1101/2021.12.14.21267615 · Cited by 2,420
Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine
Thomas, S. J., Moreira, E. D., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Polack, F. P., Zerbini, C., et al. (2021) · doi:10.1101/2021.07.28.21261159 · Cited by 1,640
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months
Thomas, S. J., Moreira, E. D., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Polack, F. P., Zerbini, C., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2110345 · Cited by 1,640
Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase
El Sahly, H. M., Baden, L. R., Essink, B., Doblecki-Lewis, S., Martin, J. M., Anderson, E. J., Campbell, T. B., Clark, J., Jackson, L. A., Fichtenbaum, C. J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2113017 · Cited by 641
Plasma Neutralization of the SARS-CoV-2 Omicron Variant
Schmidt, F., Muecksch, F., Weisblum, Y., Da Silva, J., Bednarski, E., Cho, A., Wang, Z., Gaebler, C., Caskey, M., Nussenzweig, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmc2119641 · Cited by 432 · cited 2×
“Our study sample included tests from employees who were (1) 14 unvaccinated at the time of testing, (2) vaccinated with two doses of BNT162b2 or 15 mRNA1273 >14 days prior to testing (fully vaccinated), or (3) vaccinated with three 16 doses of BNT162b2 or mRNA1273 >7 days prior to testing (boosted).”
BackgroundMethodThompson, M. G., Natarajan, K., Irving, S. A., Rowley, E. A., Griggs, E. P., Gaglani, M., Klein, N. P., Grannis, S. J., DeSilva, M. B., Stenehjem, E., et al. (2022) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7104e3 · Cited by 398
Research works printed but not linked: 12
- Lyngse, 2021, SARS-CoV-2 omicron VOC transmission in Danish households, 10.1101/2021.12.27.21268278 · DOI
- Accorsi, 2022, Association between 3 doses of mRNA COVID-19 vaccine and symptomatic infection caused by the SARS-CoV-2 Omicron and Delta variants, JAMA, 327, 639, 10.1001/jama.2022.0470 · DOI · Paper page
- Andrews, 2022, Covid-19 vaccine effectiveness against the Omicron (B.1.1.529) variant, N Engl J Med, 386, 1532, 10.1056/NEJMoa2119451 · doi:10.1056/nejmoa2119451 · Paper page
- Gooch, Hospitals, health systems mandating vaccines for workers: Becker’s hospital review
- Mahraj, 2021, Developing a large-scale Covid-19 surveillance system to reopen campuses, 10.1056/CAT.21.0049 · DOI
- Baden, 2021, Phase 3 trial of mRNA-1273 during the Delta-variant surge, N Engl J Med, 385, 2485, 10.1056/NEJMc2115597 · DOI · Paper page
- Chemaitelly, 2022, Duration of protection of BNT162b2 and mRNA-1273 COVID-19 vaccines against symptomatic SARS-CoV-2 Omicron infection in Qatar, 10.1101/2022.02.07.22270568 · DOI · Paper page
- Klompas, 2022, Preventing SARS-CoV-2 transmission in health care settings in the context of the Omicron variant, JAMA, 327, 619, 10.1001/jama.2022.0262 · DOI
- Richterman, 2020, Hospital-acquired SARS-CoV-2 infection: lessons for public health, JAMA, 324, 2155, 10.1001/jama.2020.21399 · doi:10.1001/jama.2020.21399
- Yu, 2022, Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 variants, N Engl J Med, 386, 1579, 10.1056/NEJMc2201849 · DOI · Paper page
- Lyngse, 2022, Transmission of SARS-CoV-2 Omicron VOC subvariants BA.1 and BA.2: evidence from Danish households, 10.1101/2022.01.28.22270044 · DOI
- Kirsebom, 2022, COVID-19 vaccine effectiveness against the Omicron BA.2 variant in England, 10.1016/S1473-3099(22)00309-7 · DOI · Paper page
Cited by
Evaluation of Waning of SARS-CoV-2 Vaccine–Induced Immunity: A Systematic Review and Meta-analysis
Menegale, F., Manica, M., Zardini, A., Guzzetta, G., Marziano, V., d'Andrea, V., Trentini, F., Ajelli, M., Poletti, P., & Merler, S. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.10650 · Cited by 280
Rahman, M. O., Kamigaki, T., Thandar, M. M., Haruyama, R., Yan, F., Shibamura-Fujiogi, M., Khin Maung Soe, J., Islam, M. R., Yoneoka, D., Miyahara, R., et al. (2023) · BMJ Open · doi:10.1136/bmjopen-2023-076892 · Cited by 29
Guo, K., Ni, P., Chang, S., Jin, Y., Duan, G., & Zhang, R. (2023) · American Journal of Infection Control · doi:10.1016/j.ajic.2023.02.005 · Cited by 12
Waning of SARS-CoV-2 vaccine-induced immunity: A systematic review and secondary data analysis
Menegale, F., Manica, M., Zardini, A., Guzzetta, G., Marziano, V., d’Andrea, V., Trentini, F., Ajelli, M., Poletti, P., & Merler, S. (2022) · doi:10.1101/2022.07.04.22277225 · Cited by 1
Metadata
- Authors
- Richterman, A., Behrman, A., Brennan, P. J., O’Donnell, J. A., Snider, C. K., & Chaiyachati, K. H.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2022-07-06
- Volume
- 76
- Issue
- 3
- Pages
- e319-e326
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W4282943565
- Cited by
- 24
- References
- 7
- FWCI
- 2.72
- Type
- journal article
- Language
- en
- Open access
- green
- Funders
- National Institutes of Health
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Durability of Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Booster Vaccine Protection Against Omicron Among Healthcare Workers With a Vaccine Mandate. https://app.cochat.ai/papers/10.1093/cid/ciac454
- The paper
- Richterman, A., Behrman, A., Brennan, P. J., O’Donnell, J. A., Snider, C. K., & Chaiyachati, K. H. (2023). Durability of Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Booster Vaccine Protection Against Omicron Among Healthcare Workers With a Vaccine Mandate. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciac454
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.